T
0.345
0.00 (-0.72%)
| Penutupan Terdahulu | 0.348 |
| Jumlah Dagangan | 680,539 |
| Harga / Jualan (P/S) | 23.98 |
| Harga / Buku (P/B) | 1.45 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.15 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.81% |
| Nisbah Semasa (MRQ) | 6.68 |
| Aliran Tunai Operasi (OCF TTM) | -84.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.05 M |
| Pulangan Atas Aset (ROA TTM) | -41.71% |
| Pulangan Atas Ekuiti (ROE TTM) | -76.21% |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -0.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -24.2% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 2.7 |
| Skor Akhir | -0.21 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tenaya Therapeutics, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| TNYA | - | - | - | 1.45 |
| IPA | 96 M | - | - | 5.98 |
| CRVO | - | - | - | 1.54 |
| HALO | - | - | - | 103.55 |
| CELU | - | - | - | - |
| RVPH | - | - | - | 0.290 |
|
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.72% |
| % Dimiliki oleh Institusi | 59.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Millennium Management Llc | 30 Jun 2026 | 6,429,648 |
| Citadel Advisors Llc | 30 Jun 2026 | 4,566,774 |
| Empery Asset Management, Lp | 30 Jun 2026 | 3,863,115 |
| Renaissance Technologies Llc | 30 Sep 2026 | 2,960,200 |
| Gsa Capital Partners Llp | 30 Jun 2026 | 2,669,033 |
| Burkehill Global Management, Lp | 30 Jun 2026 | 2,000,000 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 1,555,500 |
| Raiffeisen Bank International Ag | 30 Sep 2026 | 1,200,000 |
| Euclidean Capital Llc | 30 Jun 2026 | 1,015,705 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Nov 2026 | Yahoo Finance |
Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates
Tenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +20.00% and +61.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory Interactions for Pivotal Trial Planning Anticipated… |
| 14 Sep 2026 | Yahoo Finance |
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya… |
| 10 Sep 2026 | Yahoo Finance |
Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck
Stocks were down on Thursday as investors watched for stress signs in the bond market as long dated bond yields as oil prices remain elevated . |
| 03 Sep 2026 | Yahoo Finance |
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that… |
| 18 Aug 2026 | Yahoo Finance |
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion. Hyllengren, who said he had be… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |